Incorporating biomarkers into clinical trial designs: points to consider

Article metrics

In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2

References

  1. 1

    Regulatory Innovation. BioCentury 39, A1–A28, September 13, 2010.

  2. 2

    Jallal, B. Euro. Pharm. Rev. 16, 29–31 (2011).

  3. 3

    LaVallee, T. Onc. News. 6, 52 (2011).

  4. 4

    Heinemann, V. et al. Cancer Treat. Rev. 35, 262–271 (2009).

  5. 5

    Beckman, R.A. et al. Nat. Rev. Drug Discov. 10, 735–748 (2011).

  6. 6

    Sikorski, R. & Yao, B. Sci. Transl. Med. 1, 10ps11 (2009).

  7. 7

    Barker, A.D. et al. Clin. Pharmacol. Ther. 86, 97–100 (2009).

  8. 8

    Fleming, T. & Richardson, B.A. J. Infect. Dis. 190, 666–674 (2004).

  9. 9

    Patlak, M., Nass, S.J. & Balogh, E. The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care. http://books.nap.edu/openbook.php?record_id=13101 (The National Academies Press, Washington, DC, 2011).

  10. 10

    D'Agostino, R.B. N. Engl. J. Med., 365, e2 (2011).

  11. 11

    Chen, K. & Shan, M. Contemp. Clin. Trials 29, 32–41 (2008).

  12. 12

    Vickers, A.J., Ballen, V. & Scher, H.I. Clin. Cancer Res. 13, 972–976 (2007).

  13. 13

    Thall, P.F. UT MD Anderson Cancer Center Department of Biostatistics Working Paper Series http://biostats.bepress.com/mdandersonbiostat/paper35/ (2007).

  14. 14

    Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).

  15. 15

    Maitland, M. et al. J. Clin. Oncol. 29, 3109–3111 (2011).

  16. 16

    Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).

Download references

Author information

Correspondence to Edward Bradley.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bradley, E. Incorporating biomarkers into clinical trial designs: points to consider. Nat Biotechnol 30, 596–599 (2012) doi:10.1038/nbt.2296

Download citation

Further reading